A Study of ONO-7475 in Patients With Acute Leukemias
\[Updated\]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability and ii) preliminary efficacy of the combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid leukemia.
Acute Leukemia|Myelodysplastic Syndromes
DRUG: ONO-7475 3mg once daily|DRUG: ONO-7475 6mg once daily|DRUG: ONO-7475 10mg once daily|DRUG: ONO-7475 6mg + Venetoclax (70-400mg)
Incidence of Adverse Events (Part A), Incidence of most common (frequency of \>20%) treatment-emergent adverse events (TEAEs) of CTCAE grade 3 or higher by preferred terms coded with MedDRA version 23.1.

CTCAE = Common Terminology Criteria for Adverse Events (CTCAE) version 4.03., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 32 months).|Incidence of Serious Adverse Events (Part A), Incidence (frequency ≥ 2 participants) of serious treatment-emergent adverse events (all CTCAE grades) by preferred terms coded with MedDRA version 23.1.

CTCAE = Common Terminology Criteria for Adverse Events (CTCAE) version 4.03., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 32 months).|Clinically Significant Changes in Ophthalmology Examination Parameters (Part A), Incidence (all participants) of ophthalmological treatment-emergent adverse events (all CTCAE grades) by preferred terms coded with MedDRA Version 23.1.

CTCAE = Common Terminology Criteria for Adverse Event version 4.03., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 32 months).|Clinically Significant Changes in 12-Lead Electrocardiogram Parameters (Part A), Participants with clinically significant changes in 12-lead Electrocardiogram (ECG) parameters., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 32 months).|Incidence of Adverse Events (Part D), Incidence of most common (frequency \> 20%) treatment-emergent adverse events (TEAEs) of CTCAE grade 3 or higher by preferred term coded with MedDRA version 23.1.

CTCAE = Common Terminology Criteria for Adverse Events (CTCAE) version 4.03., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 21 months).|Incidence of Serious Adverse Events (Part D), Incidence (frequency ≥ 2 participants) of serious treatment-emergent adverse events (all CTCAE grades) by preferred terms coded with MedDRA version 23.1.

CTCAE = Common Terminology Criteria for Adverse Events (CTXAE) Version 4.03., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 21 months).|Complete Response (CR) / Complete Response With Partial Hematologic Recovery (CRh) Rate (Part D), Summary of complete response (CR) and complete response with partial hematologic recovery (CRh) rate., From baseline up to maximum of 21 months
Determination of Maximum Tolerated Dose (MTD) by Assessing Dose Limiting Toxicities (DLT) (Part A), Dose Limiting Toxicities (DLT) Criteria: 1) ONO-7475-related ≥Grade 4 hematologic toxicity, 2) any pre-existing condition that worsens by more than 1 grade or to Grade 4, not caused by AML, 3) any ≥Grade 3 non-hematologic toxicity not caused by AML (exception: alopecia, nausea, vomiting, fatigue, headache, chills, electrolyte disturbances), 4) ≥Grade 2 blurred vision (confirmed by loss of 15 letters or more on Early Treatment Diabetic Retinopathy chart and by ophthalmological and retinal assessments) not caused by AML, 5) ≥Grade 2 clinically significant changes in night blindness not caused by AML, 6) ≥Grade 3 differentiation syndrome, 7) death not caused by AML, and 8) any other event determined by the Safety Review Committee for dosing stop.

Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 was applied for toxicity grading., 28 days|Pharmacokinetics (Cmax and Ctrough) of ONO-7475 (Part A), Part A Pharmacokinetics Cmax of ONO-7475 assessed on day 1 and day 28, and Ctrough of ONO-7475 assessed on day 28 (pre-dose)., Day 1 and Day 28|Pharmacokinetics (Tmax) of ONO-7475 (Part A), Part A Pharmacokinetics Tmax of ONO-7475 assessed on day 1 and day 28., Day 1 and Day 28|Pharmacokinetics (AUC) of ONO-7475 (Part A), Part A Pharmacokinetics (AUC0-10h) of ONO-7475 assessed on day 1 and day 28, (AUC0-24h) of ONO-7475 assessed on day 1., Day 1 and Day 28|Pharmacokinetics (T1/2) of ONO-7475 (Part A), Part A Pharmacokinetics T1/2 of ONO-7475 assessed on day 1 and day 28. T1/2 was not calculable due to insufficient evaluable data., Day 1 and Day 28|Pharmacokinetics of the Food Effect on ONO-7475 (Part A), Part A Pharmacokinetics (Cmax, Tmax, AUC, T1/2, Ctrough) of the food effect on ONO-7475 assessed as ratio of Day57/Day28 and comparing pharmacokinetic parameters from dosing under fasted and non-fasted conditions assessed in 6mg and 10mg dose groups., Day 28 and Day 57|Pharmacodynamics (Axl and Mer Inhibition) of ONO-7475 (Part A), Assessment of the pharmacodynamic activity by measurement of Axl and Mer inhibition using a Plasma Inhibitory Activity (PIA) assay. PIA is a flow cytometry assay measuring auto-phosphorylation in Axl-expressing Ba/F3 and Mer-expressing Ba/F3 cells, respectively the percentage of inhibition. Pre-dose samples were collected for the analysis on day 2 and day 28., Day 2 and Day 28|Overall Response Rate and Duration of Response in ONO-7475 Groups (Part A), Part A analysis of best overall response. Duration of response analysis was not performed as no response of complete remission, Morphologic complete remission with incomplete blood count recovery, morphologic leukemia-free state, or partial remission was observed., From baseline up to maximum of 32 months|Event Free Survival in ONO-7475 Groups (Part A), Part A analysis of event free survival in ONO-7475 treatment groups, From baseline up to maximum of 32 months|Pharmacokinetics (Cmax) of ONO-7475 in Treatment Group ONO-7475 + Venetoclax (Part D), Part D Pharmacokinetics (Cmax) of ONO-7475 in treatment group ONO-7475 + venetoclax., Day 29|Pharmacokinetics (Tmax) of ONO-7475 in Treatment Group ONO-7475 + Venetoclax (Part D), Part D Pharmacokinetics (Tmax) of ONO-7475 in treatment group ONO-7475 + venetoclax., Day 29|Pharmacokinetics (AUC) of ONO-7475 in Treatment Group ONO-7475 + Venetoclax (Part D), Part D Pharmacokinetics (AUC) of ONO-7475 in treatment group ONO-7475 + venetoclax., Day 29|Pharmacokinetics (T1/2) of ONO-7475 in Treatment Group ONO-7475 + Venetoclax (Part D), Part D Pharmacokinetics (T1/2) of ONO-7475 in treatment group ONO-7475 + venetoclax., Day 29|Pharmacokinetics (Cmax) of Venetoclax in Treatment Group ONO-7475 + Venetoclax (Part D), Part D Pharmacokinetics (Cmax) of Venetoclax in treatment group ONO-7475 + Venetoclax., Day 1 and Day 29|Pharmacokinetics (Tmax) of Venetoclax in Treatment Group ONO-7475 + Venetoclax (Part D), Part D Pharmacokinetics (Tmax) of Venetoclax in treatment group ONO-7475 + venetoclax., Day 1 and Day 29|Pharmacokinetics (AUC) of Venetoclax in Treatment Group ONO-7475 + Venetoclax, Part D Pharmacokinetics (AUC) of Venetoclax in treatment group ONO-7475 + venetoclax., Day 1 and Day 29|Pharmacokinetics (T1/2) of Venetoclax in Treatment Group ONO-7475 + Venetoclax (Part D), Part D Pharmacokinetics (T1/2) of Venetoclax in treatment group ONO-7475 + venetoclax., Day 29|Incidence of Adverse Events in ONO-7475 + Venetoclax Group (Part D), Part D Incidence (frequency \> 20%) and severity (CTCAE grades) of treatment-emergent adverse events in ONO-7475 + Venetoclax Group, in preferred terms coded MedDRA version 23.1.

CTCAE = common terminology criteria for adverse events (CTCAE) version 4.03., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 21 months).|Incidence of Serious Adverse Events in ONO-7475 + Venetoclax Group (Part D), Part D Incidence (frequency ≥ 2 participants) and severity (CTCAE grades) of serious treatment-emergent adverse events in ONO-7475 + Venetoclax Group (Part D), preferred term coded with MedDRA version 23.1.

CTCAE = Common Terminology Criteria for Adverse Events (CTCAE) version 4.03., From start of study drug up to 30 days after permanent discontinuation of study drug or initiation of new anti-cancer therapy, whichever occurs first (maximum of 21 months).|Overall Response Rate in ONO-7475 + Venetoclax Group (Part D), Part D Summary of best overall response in ONO-7475 + Venetoclax group., From baseline up to maximum of 21 months|Duration of Response in ONO-7475 + Venetoclax Group (Part D), Part D Duration of response in ONO-7475 6mg + Venetoclax group., From baseline up to maximum of 21 months|Event-Free Survival and Overall Survival in ONO-7475 + Venetoclax Group (Part D), Part D analysis of event free survival and overall survival in ONO-7475 6mg + Venetoclax group, From baseline up to maximum of 21 months|Transfusion Independence Rate (Part D), Part D analysis of transfusion Independence rate. Rate of maintenance of transfusion independence = percentage of patients who were transfusion independent post-baseline based upon the patients who were transfusion independent at baseline.

Calculated using the Clopper-Pearson method., From baseline up to maximum of 21 months
Part A is a dose escalation study of ONO-7475 in patients with acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes.

Part D is a dose escalation study of ONO-7475 in combination with venetoclax. ONO-7475 starting dose is selected following safety and tolerability outcome of Part A.